Solstein Capital’s DexCom DXCM Stock Holding History

Solstein Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-249	Closed	-$21.7K	–	470
2025 Q2	$21.7K	Buy	+249	New	+$19.5K	0.01%	270
2022 Q3	–	Sell	-412	Closed	-$31K	–	314
2022 Q2	$31K	Hold	412	–	–	0.02%	202
2022 Q1	$53K	Hold	412	–	–	0.03%	184
2021 Q4	$55K	Hold	412	–	–	0.03%	203
2021 Q3	$56K	Hold	412	–	–	0.03%	219
2021 Q2	$44K	Hold	412	–	–	0.05%	227
2021 Q1	$37K	Buy	+412	New	+$38.7K	0.05%	214
2020 Q4	–	Sell	-412	Closed	-$42K	–	122
2020 Q3	$42K	Hold	412	–	–	0.09%	138
2020 Q2	$42K	Hold	412	–	–	0.1%	121
2020 Q1	$28K	Hold	412	–	–	0.11%	111
2019 Q4	$23K	Buy	+412	New	+$19.5K	0.05%	172

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Solstein Capital's DXCM Position: Q3 2025 in Review

Solstein Capital sold out of DexCom (DXCM) in Q3 2025, closing a stake of 249 shares — an estimated $21.7K sold.

Solstein Capital first reported a position in DXCM in Q4 2019 and held it in 11 quarters. The position peaked at $56K in Q3 2021. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

Solstein Capital reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
Solstein Capital sold 249 DexCom shares in Q3 2025, an estimated $21.7K.
Solstein Capital first reported a position in DexCom in Q4 2019 and held it in 11 quarters.
Solstein Capital's DexCom position peaked at $56K in Q3 2021.
911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Solstein Capital's 13F filing for Q3 2025, filed 12 Nov 2025.